Pharming Group N.V. Form 6-K Summary
Reporting period and filing date: Form 6-K for April 2024, filed April 25, 2024. The filing furnishes three company press releases dated April 18–19, 2024, concerning a convertible bond refinancing and repurchase of existing debt.
Business Context
Pharming is a Netherlands-based global biopharmaceutical company developing and commercializing protein replacement therapies and precision medicines for rare and debilitating diseases. Its products and development programs include small molecules, biologics and gene therapies, serving patients in more than 30 markets.
Key Financial and Capital Structure Matters
- Pharming placed €100 million of senior unsecured convertible bonds due April 25, 2029. The offering was fully subscribed and issued at par.
- The new bonds carry a 4.50% annual coupon, payable semi-annually on April 25 and October 25, beginning October 25, 2024.
- The initial conversion price is €1.2271 per share, representing a 37.5% premium to the €0.8924 reference VWAP. Customary adjustment provisions apply.
- Net proceeds are being used to repurchase the company’s outstanding €125 million, 3.00% senior unsecured convertible bonds due 2025.
- Pharming announced the repurchase of €123.1 million, or 98.5% of the 2025 bonds outstanding, at 100% of principal value plus accrued and unpaid interest. Settlement was expected on April 26, 2024.
- Following the repurchase, approximately €1.9 million of the 2025 bonds remained outstanding. The company may be able to redeem the remaining bonds early at principal value plus accrued interest, subject to required notice and the bond terms.
- The new bonds are expected to be admitted to trading on the Open Market of the Frankfurt Stock Exchange within 30 days of issuance.
- The filing does not provide operating revenue, profit, cash flow, margin, cash balance, working-capital or liquidity figures for the reporting period.
Material Changes Versus the Prior Comparable Position
- The refinancing extends a substantial portion of convertible debt maturity from 2025 to 2029.
- The principal amount of outstanding 2025 convertible debt was reduced from €125 million to approximately €1.9 million through the cash repurchase and cancellation process.
- The coupon on the new debt is 4.50%, compared with 3.00% on the repurchased 2025 bonds, increasing the stated cash coupon on the refinanced amount.
- The transaction may result in future equity dilution if bondholders convert, although the initial conversion price is set at a premium to the reference share price.
Guidance, Outlook, Risks and Unusual Items
- Management stated that the refinancing strengthens Pharming’s financial position and enhances flexibility for executing its business strategy over the next several years.
- The company and its subsidiaries agreed to a 90-day lock-up following issuance, subject to customary exceptions.
- Pharming may redeem the new bonds at par plus accrued interest if specified conversion-parity or conversion/repurchase thresholds are met, including after May 16, 2027 if the applicable parity condition is satisfied.
- Before a physical settlement notice, Pharming may elect to settle conversions in cash and/or shares, creating potential cash requirements or equity dilution.
- The new bonds were offered only to institutional or other qualifying investors in permitted jurisdictions and were not registered for public offering in the United States. They are not intended for retail investors in the EEA or the United Kingdom.
- Forward-looking statements are subject to clinical, regulatory, commercial, competitive, technical and financing risks, including the scope and cost of clinical trials and developments affecting working-capital requirements and cash resources.
Important Facts for Investors to Verify
- Confirm completion and accounting treatment of the April 25, 2024 issuance and the April 26, 2024 repurchase settlement.
- Verify the final amount of 2025 bonds cancelled and the remaining debt balance.
- Review the final terms of the 2029 convertible bonds, including conversion adjustments, cash-versus-share settlement rights and redemption provisions.
- Assess the higher 4.50% coupon and its effect on future interest expense and liquidity.
- Evaluate potential dilution based on the €1.2271 initial conversion price and subsequent adjustment provisions.
- Review Pharming’s 2023 Annual Report and Form 20-F for operating performance, cash resources, clinical programs and risk factors, as this filing does not provide those financial metrics.